This article is more than 5 years old. Information may no longer be current.

VIDEO: MacroGenics CEO highlights potential of margetuximab in pretreated HER2-positive breast cancer

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CHICAGO — Scott Koenig, MD, PhD, president and CEO of MacroGenics, spoke with HemOnc Today at ASCO Annual Meeting about positive results from the SOPHIA study.

The study evaluated the company’s lead molecule, margetuximab, plus chemotherapy versus trastuzumab (Herceptin, Genentech) plus chemotherapy for patients with breast cancer who had progressed on standard HER2 therapy.

The study demonstrated an improvement in PFS with the margetuximab-chemotherapy regimen. Follow-up for OS — another primary endpoint — is continuing.

Koenig also provided an overview of the company’s pipeline and highlighted data updates that should be available later this year. – by Mark Leiser